Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Manufacturing Operations, regulatory affairs managers, and commercial leads from medical supply manufacturers, contract manufacturers, and distribution networks that specialize in infusion therapy, wound management, and disposable medical products. Chief procurement officers, materials management directors, infection control specialists, operating room managers, dialysis center administrators, wound care nurses, and category managers from hospital systems, ambulatory surgery centers, long-term care facilities, and home healthcare agencies comprised demand-side sources. Product segmentation was validated across disposable and reusable categories, supply chain distribution channels were confirmed, and insights on bulk purchasing dynamics, Group Purchasing Organization (GPO) contracting strategies, reimbursement coding (HCPCS/DRG), and inventory management protocols were gathered through primary research.
Primary Respondent Breakdown:
By Designation: C-level Primaries (38%), Director Level (30%), Others (32%)
By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)
Revenue mapping, procedure volume analysis, and hospital bed capacity utilization were implemented to determine global market valuation. The methodology comprised the following:
The identification of over 50 key manufacturers in North America, Europe, Asia-Pacific, and Latin America
Product mapping encompasses infusion therapy systems, wound care dressings and devices, blood collection and handling products, dialysis disposables, surgical drapes and garments, incontinence products, and glucose monitoring supplies.
Examination of annual revenues that are specific to capital equipment accessories and medical disposable portfolios, as well as those that are reported and modeled
Manufacturers that account for 72–76% of the global market share in 2024 are included in the coverage.
To derive segment-specific valuations and regional penetration rates, extrapolation is employed in conjunction with top-down (manufacturer revenue validation and distributor markup analysis) and bottom-up (hospital bed capacity × patient days × ASP by country; surgical procedure volume × supplies per procedure) approaches.
